

Nananda Col

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/1008267/publications.pdf>

Version: 2024-02-01

66
papers

6,365
citations

185998

28
h-index

114278

63
g-index

66
all docs

66
docs citations

66
times ranked

7536
citing authors

#	ARTICLE	IF	CITATIONS
1	Subclinical Thyroid Disease. JAMA - Journal of the American Medical Association, 2004, 291, 228.	3.8	1,532
2	Estimating Hip Fracture Morbidity, Mortality and Costs. Journal of the American Geriatrics Society, 2003, 51, 364-370.	1.3	744
3	Assessing the Quality of Decision Support Technologies Using the International Patient Decision Aid Standards instrument (IPDASi). PLoS ONE, 2009, 4, e4705.	1.1	374
4	Meta-analysis of vascular and neoplastic events associated with tamoxifen. Journal of General Internal Medicine, 2003, 18, 937-947.	1.3	326
5	Communicating the Uncertainty of Harms and Benefits of Medical Interventions. Medical Decision Making, 2007, 27, 681-695.	1.2	293
6	Use of Pharmacologic Interventions for Breast Cancer Risk Reduction: American Society of Clinical Oncology Clinical Practice Guideline. Journal of Clinical Oncology, 2013, 31, 2942-2962.	0.8	279
7	American Society of Clinical Oncology Clinical Practice Guideline Update on the Use of Pharmacologic Interventions Including Tamoxifen, Raloxifene, and Aromatase Inhibition for Breast Cancer Risk Reduction. Journal of Clinical Oncology, 2009, 27, 3235-3258.	0.8	254
8	Do Patient Decision Aids Meet Effectiveness Criteria of the International Patient Decision Aid Standards Collaboration? A Systematic Review and Meta-analysis. Medical Decision Making, 2007, 27, 554-574.	1.2	237
9	Revisiting the Duration of Vasomotor Symptoms of Menopause: A Meta-Analysis. Journal of General Internal Medicine, 2008, 23, 1507-1513.	1.3	198
10	Clarifying values: an updated review. BMC Medical Informatics and Decision Making, 2013, 13, S8.	1.5	188
11	American Society of Clinical Oncology Technology Assessment of Pharmacologic Interventions for Breast Cancer Risk Reduction Including Tamoxifen, Raloxifene, and Aromatase Inhibition. Journal of Clinical Oncology, 2002, 20, 3328-3343.	0.8	187
12	Metformin and breast cancer risk: a meta-analysis and critical literature review. Breast Cancer Research and Treatment, 2012, 135, 639-646.	1.1	183
13	Subclinical Thyroid Disease. JAMA - Journal of the American Medical Association, 2004, 291, 239.	3.8	149
14	Duration of vasomotor symptoms in middle-aged women. Menopause, 2009, 16, 453-457.	0.8	140
15	Hormone Replacement Therapy After Breast Cancer: A Systematic Review and Quantitative Assessment of Risk. Journal of Clinical Oncology, 2001, 19, 2357-2363.	0.8	133
16	Design Features of Explicit Values Clarification Methods. Medical Decision Making, 2016, 36, 453-471.	1.2	90
17	Internet Use Among Community College Students: Implications in Designing Healthcare Interventions. Journal of American College Health, 2004, 52, 197-202.	0.8	86
18	Gender differences and factors associated with the receipt of thrombolytic therapy in patients with acute myocardial infarction: A community-wide perspective. American Heart Journal, 1996, 131, 43-50.	1.2	68

#	ARTICLE	IF	CITATIONS
19	Balancing the presentation of information and options in patient decision aids: an updated review. <i>BMC Medical Informatics and Decision Making</i> , 2013, 13, S6.	1.5	67
20	Effect of a patient decision aid (PDA) for type 2 diabetes on knowledge, decisional self-efficacy, and decisional conflict. <i>BMC Health Services Research</i> , 2015, 16, 10.	0.9	56
21	What Families Need and Physicians Deliver: Contrasting Communication Preferences Between Surrogate Decision-Makers and Physicians During Outcome Prognostication in Critically Ill TBI Patients. <i>Neurocritical Care</i> , 2017, 27, 154-162.	1.2	56
22	The Discrepancy between Observational Studies and Randomized Trials of Menopausal Hormone Therapy: Did Expectations Shape Experience?. <i>Annals of Internal Medicine</i> , 2003, 139, 923.	2.0	46
23	Effects of Design Features of Explicit Values Clarification Methods. <i>Medical Decision Making</i> , 2016, 36, 760-776.	1.2	44
24	Decision Aids and Shared Decision-Making in Neurocritical Care: An Unmet Need in Our NeuroICUs. <i>Neurocritical Care</i> , 2015, 23, 127-130.	1.2	42
25	Whose Preferences Matter? A Patient-Centered Approach for Eliciting Treatment Goals. <i>Medical Decision Making</i> , 2018, 38, 44-55.	1.2	41
26	Factors associated with treatment of women with osteoporosis or osteopenia from a national survey. <i>BMC Women's Health</i> , 2012, 12, 1.	0.8	39
27	Frequency of inclusion of patients with cardiogenic shock in trials of thrombolytic therapy. <i>American Journal of Cardiology</i> , 1994, 73, 149-157.	0.7	33
28	A latent class typology of young women smokers. <i>Addiction</i> , 2007, 102, 1310-1319.	1.7	32
29	Can Computerized Decision Support Help Patients Make Complex Treatment Decisions? A Randomized Controlled Trial of an Individualized Menopause Decision Aid. <i>Medical Decision Making</i> , 2007, 27, 585-598.	1.2	29
30	Coronary Heart Disease and Stroke with Aromatase Inhibitor, Tamoxifen, and Menopausal Hormone Therapy Use. <i>Clinical Breast Cancer</i> , 2006, 6, S58-S64.	1.1	26
31	Interprofessional education about shared decision making for patients in primary care settings. <i>Journal of Interprofessional Care</i> , 2011, 25, 409-415.	0.8	26
32	Estrogen deficiency symptom management in breast cancer survivors in the changing context of menopausal hormone therapy. <i>Seminars in Oncology</i> , 2003, 30, 776-788.	0.8	25
33	Menopausal hormone therapy after breast cancer. <i>Lancet, The</i> , 2004, 363, 410-411.	6.3	24
34	Women Like Me. <i>Journal of Psychosocial Oncology</i> , 2002, 20, 39-56.	0.6	20
35	Improving patient-provider communication about chronic pain: development and feasibility testing of a shared decision-making tool. <i>BMC Medical Informatics and Decision Making</i> , 2020, 20, 267.	1.5	20
36	The health care information directive. <i>BMC Medical Informatics and Decision Making</i> , 2001, 1, 1.	1.5	18

#	ARTICLE	IF	CITATIONS
37	Development of a patient decision aid for type 2 diabetes mellitus for patients not achieving glycemic control on metformin alone. <i>Patient Preference and Adherence</i> , 2015, 9, 609.	0.8	18
38	Benefit/risk for adjuvant breast cancer therapy with tamoxifen or aromatase inhibitor use by age, and race/ethnicity. <i>Breast Cancer Research and Treatment</i> , 2015, 154, 609-616.	1.1	18
39	Bisphosphonates and breast cancer incidence and recurrence. <i>Breast Disease</i> , 2011, 33, 93-101.	0.4	17
40	Bisphosphonates and Breast Cancer Prevention. <i>Anti-Cancer Agents in Medicinal Chemistry</i> , 2012, 12, 144-150.	0.9	17
41	Development of a shared decision-making tool to assist patients and clinicians with decisions on oral anticoagulant treatment for atrial fibrillation. <i>Current Medical Research and Opinion</i> , 2015, 31, 2261-2272.	0.9	17
42	Ovarian suppression in combination endocrine adjuvant therapy in premenopausal women with early breast cancer. <i>Breast Cancer Research and Treatment</i> , 2017, 161, 185-190.	1.1	17
43	Hormone Therapy for the Prevention of Bone Loss in Menopausal Women with Osteopenia. <i>Drugs</i> , 2007, 67, 2311-2321.	4.9	15
44	The Use of Gene Tests to Detect Hereditary Predisposition to Chronic Disease: Is Cost-Effectiveness Analysis Relevant?. <i>Medical Decision Making</i> , 2003, 23, 441-448.	1.2	13
45	Perceived Effectiveness, Self-efficacy, and Social Support for Oral Appliance Therapy Among Older Veterans With Obstructive Sleep Apnea. <i>Clinical Therapeutics</i> , 2016, 38, 2407-2415.	1.1	13
46	Impact and Feasibility of Personalized Decision Support for Older Patients with Diabetes: A Pilot Randomized Trial. <i>Medical Decision Making</i> , 2017, 37, 611-617.	1.2	13
47	Should We Use the IMPACT-Model for the Outcome Prognostication of TBI Patients? A Qualitative Study Assessing Physicians'™ Perceptions. <i>MDM Policy and Practice</i> , 2018, 3, 238146831875798.	0.5	12
48	Measuring the impact of menopausal symptoms on quality of life. <i>Menopause</i> , 2009, 16, 843-845.	0.8	10
49	Commentary-Surgical Decisions after Breast Cancer: Can Patients Be Too Involved in Decision Making?. <i>Health Services Research</i> , 2005, 40, 769-780.	1.0	9
50	Evaluation of a Novel Preference Assessment Tool for Patients with Multiple Sclerosis. <i>International Journal of MS Care</i> , 2018, 20, 260-267.	0.4	9
51	Efficacy of a patient decision aid for improving person-centered decision-making by older adults with obstructive sleep apnea. <i>Journal of Clinical Sleep Medicine</i> , 2021, 17, 121-128.	1.4	9
52	Survival Impact of Tamoxifen Use for Breast Cancer Risk Reduction: Projections from a Patient-Specific Markov Model. <i>Medical Decision Making</i> , 2002, 22, 386-393.	1.2	8
53	Using Internet technologies to improve and simplify counseling about menopause: The WISDOM website. <i>Maturitas</i> , 2007, 57, 95-99.	1.0	8
54	Changing Patients'™ Treatment Preferences and Values with a Decision Aid for Type 2 Diabetes Mellitus: Results from the Treatment Arm of a Randomized Controlled Trial. <i>Diabetes Therapy</i> , 2018, 9, 803-814.	1.2	8

#	ARTICLE	IF	CITATIONS
55	Should menopausal women at increased risk for breast cancer use tamoxifen, raloxifene, or hormone therapy?: A framework for personalized risk assessment and counseling. <i>Journal of Cancer Education</i> , 2007, 22, 10-14.	0.6	7
56	Risks and benefits of therapy with menopausal hormones versus selective estrogen-receptor modulators in peri- and postmenopausal women at increased breast cancer risk. <i>Menopause</i> , 2008, 15, 804-809.	0.8	5
57	Patient-Provider Communication With Older Adults About Sleep Apnea Diagnosis and Treatment. <i>Behavioral Sleep Medicine</i> , 2017, 15, 423-437.	1.1	5
58	Patient-Reported Usability of Positive Airway Pressure Equipment Is Associated With Adherence in Older Adults. <i>Sleep</i> , 2017, 40, .	0.6	4
59	Consumers and Clinical Decision Support. , 2014, , 741-769.		2
60	A Novel Tool to Improve Shared Decision Making and Adherence in Multiple Sclerosis: Development and Preliminary Testing. <i>MDM Policy and Practice</i> , 2019, 4, 238146831987913.	0.5	2
61	The pitfalls of non-evidence-based guidelines. <i>Menopause</i> , 2006, 13, 334-337.	0.8	1
62	Re: Pharmacogenomic Variation of CYP2D6 and the Choice of Optimal Adjuvant Endocrine Therapy for Postmenopausal Breast Cancer: A Modeling Analysis. <i>Journal of the National Cancer Institute</i> , 2008, 100, 1331-1332.	3.0	1
63	Postmenopausal Women with DCIS Post-Mastectomy: A Potential Role for Aromatase Inhibitors. <i>Breast Journal</i> , 2012, 18, 299-302.	0.4	1
64	Development of a Program Promoting Personâ€Centered Care of Older Adults with Sleep Apnea. <i>Journal of the American Geriatrics Society</i> , 2019, 67, 2204-2207.	1.3	1
65	Hormone replacement therapy after diagnosis of breast cancer did not increase breast cancer recurrence. <i>Evidence-Based Obstetrics and Gynecology</i> , 2002, 4, 94-95.	0.3	0
66	Questioning the Accuracy of a Recent Review of Osteoporosis Medications. <i>Annals of Internal Medicine</i> , 2009, 150, 423.	2.0	0